Antisense therapy for B cell lymphomas

Cancer Surveys

Volumn 30, Issue , 1997, Pages 311-325

  Cotter, Finbarr E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; SINGLE STRANDED DNA;

ARTICLE; B CELL LYMPHOMA; CELL DEATH; DNA REPLICATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE TARGETING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN ANALYSIS; TARGET CELL;

GENES, BCL-2; GENES, MYC; HUMANS; LYMPHOMA, B-CELL; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0030866768     PISSN: 02612429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Agrawal S, Temsamani J and Tang J (1991) Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proceedings of the National Academy of Sciences of the USA 88 7595-7599
2. Bacon T and Wickstrom E (1991) Walking along human c-myc mRNA with antisense oligode-oxynucleotides: maximum efficacy at the 5′ cap region. Oncogene Research 6 13-19
3. Bancroft G, Bosnia M, Bosma G and Unanue E (1986) Regulation of macrophage la expression in mice with severe combined immunodeficiency: induction of la expression by a T cell independent mechanism. Journal of Immunology 137 4-9
4. Bancroft G, Schreiber R and Unanue ER (1989) T cell-independent macrophage activation in scid mice. Current Topics in Microbiology and Immunology 152 235-242
5. Bennett CF, Chiang MY, Chan H, Shoemaker JE, Mirabelli CK (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Molecular Pharmacology 41 1023-1033
6. Bishop JM (1991) Molecular themes in oncogenesis. Cell 64 235-248
7. Bishop MR, Iversen PL, Bayever E et al. (1996) Phase I trial of an antisense oligonucleotide OL(1) p53 in haematologic malignancies. Journal of Clinical Oncology 14 1320-1326
8. Boiziau C, Kurfurst R, Cazenave G, Roig V, Thuong N and Toulme J-J (1991) Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism. Nucleic Acids Research 19 1113-1119
9. Bosnia G, Custer R and Bosnia M (1983) A severe combined immunodeficiency mutation in the mouse. Nature 301 527-530
10. Brenner M, Rill D, Moen R et al. (1993) Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341 85-86
11. Calabretta B, Skorski T, Ratajczak MZ and Gewirtz AM (1996) Antisense strategies in the treatment of leukemias. Seminars in Oncology 23 78-87
12. Clark RE (1995) Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia. Leukemia and Lymphoma 19 189-195
13. Cotter F (1993) Molecular pathology of lymphomas. Cancer Surveys 16 157-174
14. Cotter F, Johnson P, Hall P et al. (1994) Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9 3049-3055
15. Cotter FE, Corbo M, Raynaud F et al. (1996) Bcl-2 antisense therapy in lymphoma: in vitro and in vivo mechanisms, efficacy, pharmacokinetics and toxicity studies. Annals of Oncology 7 (Supplement 3) 32
16. Crowley N, Vervaert C and Seigler H (1992) Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells. Cancer Research 52 394-399
17. Daaka Y and Wickstrom E (1990) Target dependence of antisense oligodeoxynucleotide inhibition of c-H-ras p21 expression and focus formation in T24-transformed NIH3T3 cells. Oncogene Research 5 267-275
18. Dash P, Lotan I, Knapp M, Kandel E and Goelet P (1987) Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proceedings of the National Academy of Sciences of the USA 84 7896-7900
19. de Kroon J, Kluin P, Kluin-Nelemans H, Willemze R and Falkenberg J (1994) Homing and antigenic characterization of a human non-Hodgkin's lymphoma B cell line in severe combined immunodeficient (SCID) mice. Leukemia 8 1385-1391
20. Dorshkind K, Keller G, Phillips R, Miller R and Bosma M (1984) Functional status of cells from lymphoid and myeloid tissues in mice with severe combined immunodeficiency disease. Journal of Immunology 132 1804-1808
21. Dorshkind K, Pollack S, Bosma M and Phillips R (1985) Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid) Journal of Immunology 134 3788-3801
22. Eder P, DeVine R, Dagle J and Walder J (1991) Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Research and Development 1 141-151
23. Ghetie M-A, Richardson J, Tucker T, Jones D, Uhr J and Vitetta E (1990) Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. International Journal of Cancer 45 481-485
24. Ghetie M-A, Richardson J, Tucker T, Jones D, Uhr J and Vitetta E (1991) Antitumor activity of Fab′ and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Research 51 5876-5880
25. Ghetie M-A, Tucker K, Richardson J, Uhr J and Vitetta E (1994) Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood 84 702-707
26. Ghosh M and Ghosh K (1991) Oligodeoxynucleotide analogs as informational drugs to regulate translation. Nucleic Acids Symposium Series 24 139-142
27. Goodchild J (1988) Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proceedings of the National Academy of Sciences of the USA 85 5507-5511
28. Helene C and Toulme JJ (1990) Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochimica et Biophysica Acta 1046 99-125
29. Holt J, Redner R and Nienhuis A (1988) An oligomer complimentary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Molecular and Cellular Biology 8 967-973
30. Iversen P (1991) In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anti-Cancer Drug Design 6 531-538
31. Kreig A, Gmelig-Meyling F, Gourley M, Kisch W, Chrisey L and Steinberg A (1991) Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. Antisense Research and Development 1 161-171
32. Lauzon R, Siminovitch K, Fulop G, Phillis R and Roder J (1986) An expanded population of natural killer cells in mice with severe combined immunodeficiency (SCID) lack rearrangement and expression of T cell receptor genes. Journal of Experimental Medicine 164 1797-1802
33. Lima WF, Monia BP, Ecker DJ and Freier SM (1992) Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry 31 12055-12061
34. Loke S, Stein C, Zhang X et al. (1989) Characterization of oligonucleotide transport into living cells. Proceedings of the National Academy of Sciences of the USA 86 3474-3478
35. McManaway M, Neckers L, Loke S et al. (1990) Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 335 808-811
36. Miller P (1989) Non-ionic antisense oligonucleotides, In: Cohen J (ed). Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, pp 79-95, Macmillan, London
37. Milligan J, Mattcucci M and Martin J (1993) Current concepts in antisense drug design. Journal of Medicinal Chemistry 36 1923-1937
38. Monia BP, Johnston JF, Ecker DJ, Zounes MA, Lima WF and Freir SM (1992) Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. Journal of Biological Chemistry 267 19954-19962
39. Monia BP, Johnston JF, Geiger T, Muller M and Fabbro D (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Medicine 2 668-675
40. Nielsen PE, Egholm M, Berg RH and Buchardt O (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254 1497-1500
41. Pocock C, Al-Mahdi N, Hall P, Morgan G and Cotter F (1993) In vivo suppression of B-cell lymphoma with BCL-2 antisense oligonucleotides. Blood 82 (Supplement 1) 200a [Abstract]
42. Pocock C, Malone M, Booth M et al. (1995) BCL-2 expression by leukaemic blasts in a SCID mouse model of biphenotypic leukaemia model associated with the t(4;11)(q21;q23) translocation. British Journal of Haematology 90 855-867
43. Ratajczak M, Kant J, Luger S et al. (1992) In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proceedings of the National Academy of Sciences of the USA 89 11823-11827
44. Reed J, Stein C, Subasinghe C et al. (1990a) Antisense-mediated inhibition of BCL2 protoon-cogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Research 50 6565-6570
45. Reed J, Cuddy M, Haldar S et al. (1990b) BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. Proceedings of the National Academy of Sciences of the USA 87 3660-3664
46. Skorski T, Neiborowska-Skorska M, Nicolaides N et al. (1994) Suppression of Philadelphia leukemic cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proceedings of the National Academy of Sciences of the USA 91 4504-4508
47. Stein C and Cohen J (1989) Phosphorothioate oligodeoxynucleotide analogues, In: Cohen J (ed). Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, pp 97-117, Macmillan, London
48. Stein C, Cleary A, Yakubov L and Lederman S (1993) Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of HIV-1 gp120. Antisense Research and Development 3 19-31
49. Szczylik C, Skorski T, Nicolaides N et al. (1991) Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253 562-565
50. Walder R and Walder J (1988) Role of RNase-H in hybrid-arrested translation by antisense oligonucleotides. Proceedings of the National Academy of Sciences of the USA 85 5011-5015
51. Webb A, Cunningham D, Cotter F et al. (1996) Phase I Bcl-2 antisense trial: preliminary results. Annals of Oncology 7 (Supplement 3) 32
52. Wellstein A, Zugmaier G, Califano J, Kern F, Paik S and Lippman M (1991) Tumor growth dependent of Kaposi's sarcoma derived fibroblast growth factor inhibited by pentosan polysulfate. Journal of the National Cancer Institute 83 716-720
53. Wickstrom EL, Bacon T, Gonzalez A, Freeman D, Lyman G and Wickstrom E (1988) Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proceedings of the National Academy of Sciences of the USA 85 1028-1032
54. Wintersberger U (1990) Ribonucleases H of retroviral and cellular origin. Pharmacology and Therapeutics 48 259-280
55. Wittung P, Kajanus J, Edwards K et al. (995) Phospholipid membrane permeability of peptide nucleic acid. FEBS Letters 375 27-29
56. Yakubov L, Deeva E, Zarytova V et al. (1989) Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proceedings of the National Academy of Sciences of the USA 86 6454-6458
57. Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O and Tokunaga T (1992) Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. Journal of Immunology 148 4072-4076
58. Zamecnik P and Stephensen M (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proceedings of the National Academy of Sciences of the USA 75 280-284
59. Zugmaier G, Lippman M and Wellstein A (1993) Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. Journal of the National Cancer Institute 84 1716-1724